ICER Report on Lecanemab: Efficacy, Cost, and Equity Concerns for Alzheimer’s Treatment

By Staff Writer

May 1, 2023

The Institute for Clinical and Economic Review has released a report on lecanemab, an anti-amyloid monoclonal antibody approved by the FDA for the treatment of Alzheimer’s disease. The report found that while lecanemab showed a statistically significant 27% slowing of cognitive decline compared to placebo, there are concerns about the potential harm from amyloid-related imaging abnormalities. The report also found that lecanemab’s annual price of $26,500 exceeds commonly used cost-effectiveness thresholds, and recommended efforts to achieve affordability and access. The report calls for all stakeholders to address health inequities in introducing new treatments for Alzheimer’s disease, and for manufacturers to follow the example of the lecanemab manufacturer in sharing transparent pricing justifications and releasing all patient-level data.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.